Johns Hopkins University School of Medicine, United States.
Johns Hopkins University School of Medicine, United States.
J Subst Abuse Treat. 2018 Feb;85:56-60. doi: 10.1016/j.jsat.2016.12.006. Epub 2016 Dec 24.
Extended-release naltrexone (XR-NTX) blocks the effects of opioids for 4weeks, yet many patients continue to use them. To learn more about why this occurs, we collected self-reports on subjective effects and drug use factors from participants' most recent heroin/opiate use while under XR-NTX blockade.
Participants (n=38) were unemployed, heroin-dependent adults enrolled in a randomized controlled trial evaluating employment-based incentives to promote adherence to XR-NTX. A subset of participants (n=18) were asked to complete a survey about their most recent use of heroin/opiates when they provided an opiate-positive urine sample while under XR-NTX blockade. Surveys were administered weekly, and participants could complete multiple surveys throughout the trial. Participants reported how high they were (11-point scale; 0=not at all, 10=extremely), how much heroin/opiates they took (less, more, or about the same as usual before starting naltrexone), whether they used cocaine at the same time, and the routes of administration for heroin/opiates and cocaine (if used). All analyses were descriptive.
Of the 107 surveys, 75.7% indicated being "not at all" high the last time heroin/opiates were used. 75.5% of surveys reported opiate amounts that were less than usual, and only 7.5% reported amounts larger than usual. Cocaine was used at the same time as heroin for 57.9% of surveys but typically through a different route (74.2%).
Using heroin/opiates while under XR-NTX blockade is not strongly associated with self-reports of high, taking larger than normal amounts of opiates, or taking opiates and cocaine simultaneously via the same route. Future research should incorporate measures of naltrexone concentration and more comprehensive and frequent assessments using ecological momentary assessment.
缓释纳曲酮(XR-NTX)可阻断阿片类药物的作用长达 4 周,但许多患者仍继续使用。为了更深入地了解发生这种情况的原因,我们收集了参与者在 XR-NTX 阻断期间最近一次使用海洛因/阿片类药物时的主观效应和药物使用因素的自我报告。
参与者(n=38)为失业的、依赖海洛因的成年人,他们参加了一项评估以就业为基础的激励措施来促进对 XR-NTX 依从性的随机对照试验。一小部分参与者(n=18)在 XR-NTX 阻断期间提供阿片类阳性尿液样本时,被要求完成一项关于他们最近使用海洛因/阿片类药物的调查。调查每周进行一次,参与者可以在整个试验期间完成多次调查。参与者报告他们的感觉有多高(11 分制;0=一点也不,10=非常高),他们服用了多少海洛因/阿片类药物(少于、多于或与开始使用纳曲酮之前相同),他们是否同时使用可卡因,以及海洛因/阿片类药物和可卡因的给药途径(如果使用的话)。所有分析均为描述性分析。
在 107 份调查中,75.7%的人表示最后一次使用海洛因/阿片类药物时“一点也不”高。75.5%的调查报告称阿片类药物的用量少于平时,只有 7.5%的人报告用量大于平时。57.9%的调查显示可卡因与海洛因同时使用,但通常通过不同的途径(74.2%)。
在 XR-NTX 阻断期间使用海洛因/阿片类药物与自我报告的高、服用大于正常量的阿片类药物或通过相同途径同时服用阿片类药物和可卡因之间的关联并不强。未来的研究应该纳入纳曲酮浓度的测量以及使用生态瞬时评估更全面和更频繁的评估。